The round was led by Sozo Ventures with participation from Marc Benioff, along with existing investors Khosla Ventures, Founders Fund, Social Capital, AME Cloud Partners and Rethink Impact.

Neurotrack is building the digital memory health platform of the future, giving people direct access to digital tools and technology to better understand, manage and track their brain health.

Based on 30 years of scientific research, Neurotrack's comprehensive platform helps people assess their memory through the company's proprietary Imprint TM cognitive assessment, and manage memory loss and cognitive decline with the help of Neurotrack's digital therapeutic platform.

"Certain cognitive diseases such as Alzheimer's can develop 20 to 30 years before a person begins to show symptoms. We developed Neurotrack's comprehensive platform to make it easier to measure and manage their cognition," said co-founder and CEO Elli Kaplan. "We want people to know that certain types of cognitive decline are not a natural part of aging and can be prevented. With the help of our technology, Neurotrack is working to help people assess their memory health and make lifestyle changes early, so they can live long and healthy lives."

The funding will help Neurotrack continue to develop their groundbreaking platform, which includes the Imprint cognitive assessment and the forthcoming memory health program, based on large, randomized controlled scientific studies, such as the FINGER and MIND diet studies.

The memory health platform is a highly personalized program to help people make the lifestyle changes that, when combined, have the biggest impact on slowing cognitive decline.

"Not only do we have a strong belief in Elli and her team's vision, but we deeply understand the critical imperative we have to better detect and manage memory loss," said Phil Wickham, co-founder and General Partner of Sozo Ventures. "The strength of the company's position from a research, technology and data perspective is unrivaled and has the potential to meaningfully impact the long-term health of millions of people worldwide."

Neurotrack's team has years of experience developing these tools. Scientific co-founders Stuart Zola, Ph.D., Elizabeth Buffalo, Ph.D., and Cecelia Manzanares, along with a team led by Chief Science Officer Nick Bott, Psy.D., have developed Neurotrack's digital health platform, based on 30 years of scientific research.

"Using digital tools to detect and treat chronic diseases is a core part of the future of healthcare and will be increasingly important as people live longer and our aging population grows," said Jenny Abramson, Founder & Managing Partner of Rethink Impact. "As the largest US impact VC with a gender lens, we are thrilled to support Elli and Neurotrack as they expand this accessible solution, especially as the disease more adversely impacts women."

"We believe that Neurotrack's proprietary technology platform has the potential to dramatically improve the quality of care for those at risk of memory loss," added Samir Kaul, a founding general partner at Khosla Ventures. "It is time to invest in tools and technology that can support a healthcare system designed to prevent as well as treat disease."

Individuals can take the Imprint cognitive assessment by visiting www.neurotrack.com and clicking "Get Started."

About Neurotrack
Neurotrack combines science with technology to measure and manage brain health for people who recognize that cognitive decline is preventable.

Backed by 30 years of scientific research, Neurotrack has developed the only cognitive assessment tool that tracks eye movements to assess memory health, and is available to anyone with a computer and webcam. The test is supported by Neurotrack's memory health program, which provides a personalized approach to slowing or reversing the impact of cognitive decline through simple lifestyle changes.

Neurotrack is led by CEO and co-founder Elli Kaplan. Her co-founders Stuart Zola, PhD, Elizabeth Buffalo, PhD, and Cecelia Manzanarez, are leaders in the fields of neuroscience and Alzheimer's disease. The company is based in Redwood City, CA. For more information visit www.neurotrack.com.